Grail Stock Rises on Investor Optimism Despite Mixed Presentation at ASCO Conference
Shares of Grail, a multi-cancer early detection test company, rose by 11.5% following mixed investor reactions to its recent presentation at the American Society of Clinical Oncology (ASCO) conference. The data did not provide strong evidence for FDA approval or insurance coverage, particularly from Medicare.
Tickers: $GRAL
Topics: ASCO conference FDA approval Grail MCED test